Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study identified a recurrent mutation in the endothelin receptor type A associated with mandibulofacial dysostosis with alopecia, and proposed a mechanism involving increased ligand affinity due to structural changes.

This study found that patients using GLP-1 receptor agonists, specifically liraglutide, dulaglutide, and semaglutide, had a higher likelihood of being diagnosed with androgenetic alopecia, while those on exenatide showed increased odds for both androgenetic alopecia and telogen effluvium.

In this study, researchers optimized the soft drug AR antagonist 14-P1 to create candidate 39, which demonstrated effective AR antagonism and safety in a hair-growth mouse model, showing similar efficacy to pyrilutamide but with quicker onset and a lower risk of systemic toxicity.

This study evaluated the effects of autologous micrografts for androgenetic alopecia, reporting moderate improvements in hair loss reduction and hair density among most patients after treatment, with satisfactory results noted in patient satisfaction and treatment tolerability.

Gene variation affects prostate issues and hair loss.

This study tested a novel cryo-carboxy dispensing device for treating androgenetic alopecia in six volunteers and found an unexpectedly rapid and positive response, with significant hair regrowth observed by day 90, prompting early conclusion of the trial.

This study found that a chemically modified small-interfering RNA candidate, AR-27 E-Chol, effectively stimulated hair regrowth and reduced androgen receptor gene expression in a mouse model of androgenetic alopecia, indicating its potential as a novel therapeutic approach.

The trial is ongoing, but researchers are evaluating the efficacy and safety of REZPEG, a potential new therapy for severe alopecia areata, which selectively expands regulatory T cells.

This study found that supplementing with 1.5% α-ketoglutaric acid significantly improved the performance, hair follicle density, and antioxidant capacity in Rex rabbits, potentially by enhancing the Wnt signaling pathway and reducing amino acid catabolism.

In this study, ALRV5XR significantly increased hair regrowth in women with androgenetic alopecia or telogen effluvium, with no adverse events reported.

This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.

This study reports the crystallization of the human androgen receptor's ligand-binding domain with nonsteroidal ligands, which may aid in understanding the differences in binding compared to steroidal ligands.

This study found that Argireline significantly reduced the depth of periorbital wrinkles in Chinese subjects and improved skin morphology in aged mice.

AI-09 is safe, effective, and reduces wrinkles for up to 6 months.

This study demonstrated that in a mouse model of androgenic alopecia, PLGA-DUT/siAR@DPCM nanoparticles effectively delivered drugs to hair follicles, suppressed androgen-related targets, promoted cell proliferation, and showed significant therapeutic effects with minimal adverse effects, suggesting their potential for clinical application.

Blocking a protein called prostaglandin D2 might help treat hair loss.

In this pilot study, researchers found that fractional picosecond laser therapy may promote hair regrowth in men with mild-to-moderate androgenetic alopecia, with significant improvements in expert assessments and patient satisfaction observed over a four-month period, though further research is needed to confirm these findings.

In this study, aleglitazar and its metabolite M6 were evaluated for safety in non-clinical settings, revealing organ-targeting effects common to PPAR agonists but no significant tumor increase in rat carcinogenicity studies, supporting progression to Phase 3 clinical trials.

This study utilized a sequence-structure alignment approach to improve the characterization of Class A Rhodopsin GPCR superfamily, including orphan and unclassified receptors, through evolutionary analysis.

This study identified four novel and one recurrent mutation in the AIRE gene among Arab families with APS1, suggesting these contribute to the disorder.

This study reported that microneedle-assisted delivery of PEGylated recombinant human fusion collagen significantly improved hair regrowth and density in an androgenetic alopecia mouse model and in a small clinical trial with AGA patients, suggesting potential efficacy and safety for this treatment approach.

In this study, no significant change in androgen receptor gene expression was found in females with recurrent spontaneous abortion, but a mutant genotype may offer some protection against the condition.

In this study, patients with androgenic alopecia who underwent 10 sessions of 1540-nm fractional erbium glass laser treatment over 5 months experienced significant improvements in hair density and thickness, with no major safety concerns reported.

This study investigated androgen receptor expression in the scalp tissue of androgenic alopecia patients, focusing on hair follicles and sebaceous glands, using immunohistochemistry.

This study found that the novel anti-HER2 antibody RC48 demonstrated promising activity and manageable safety in patients with HER2-overexpressing, advanced gastric or gastroesophageal junction cancer after at least two prior chemotherapy lines.

This study found that pretreating concentrated growth factor with a 640 nm laser increased CD34+ stem cell activation and improved hair growth outcomes in androgenetic alopecia patients compared to non-pretreated CGF.

This study reports the discovery of LX-38, a new high-affinity non-steroidal antagonist that could provide the therapeutic benefits of current BPH and AGA treatments without the hormonal side effects, utilizing a distinct "Orthogonal T-Stacking" scaffold for binding.